ReviewCell transplantation
Role of tumor microenvironment composition and metabolism in lymphoid malignancies and therapeutic strategies.
Review in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME) plays a significant role in the occurrence, development, and prognosis of lymphomas. The mechanisms of each TME component in lymphoma and related therapeutic strategies are reviewed in this article. In the immune-related TME, regulatory T-cells (Tregs), tumor-associated macrophages (TAMs), and other immune cells mediate immune suppression and evasion. In the non-immune-related TME, cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM) are involved in tumor progression, drug resistance, and immune evasion. In addition, aberrant glucose, amino acid, and lipid metabolism in tumor cells not only sustain their rapid proliferation and survival but also reshape the TME to favor immune escape, thereby worsening patient outcomes. Various treatment strategies targeting the components of the TME and metabolic abnormalities have brought new hope for the treatment of lymphoma. Further in-depth investigation into the intricate crosstalk between the TME and lymphoma cells will be instrumental in developing more effective, personalized precision therapies to improve patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.